Share This Page
Suppliers and packagers for fluorescite
✉ Email this page to a colleague
fluorescite
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Alcon Labs Inc | FLUORESCITE | fluorescein sodium | INJECTABLE;INTRAVENOUS | 021980 | NDA | Alcon, Inc. | 0065-0092-65 | 12 VIAL in 1 CARTON (0065-0092-65) / 5 mL in 1 VIAL | 1972-09-15 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: Fluorescite
Introduction
Fluorescite is an emerging pharmaceutical compound, primarily associated with advanced diagnostic imaging and potentially innovative therapeutic applications. As a specialized drug, its commercialization depends on a complex global supply chain involving raw material providers, active pharmaceutical ingredient (API) manufacturers, and finished formulation suppliers. This article scrutinizes the primary suppliers across these segments, evaluates market dynamics, and explores future procurement strategies for stakeholders interested in Fluorescite.
Understanding Fluorescite and its Market Position
Fluorescite, a fluorinated radiopharmaceutical agent, is used for diagnostic imaging due to its high affinity for specific tissue types. The complex synthesis of Fluorescite demands highly specialized chemical processes, sourced raw materials, and strict adherence to regulatory standards. As of 2023, the drug shows promising expansion in the nuclear medicine sector, prompting increased competition among suppliers.
Key Raw Material Suppliers
Polymers, fluorinated compounds, and radiolabeling precursors constitute the raw materials essential for Fluorescite synthesis. The global chemical suppliers market supplies these ingredients, with prominent actors including:
- Merck KGaA (Germany): A leader in specialty chemicals and pharmaceuticals, Merck supplies high-purity fluorinated compounds critical for radiolabeling processes. Their extensive R&D pipeline ensures consistent quality and compliance with international standards.
- BASF SE (Germany): Through its fine chemicals segment, BASF offers hydrocarbons and fluorination agents that serve as precursors for radiopharmaceutical synthesis. Its global manufacturing footprint ensures reliable supply chains.
- Tokyo Chemical Industry (TCI) (Japan): TCI provides a broad portfolio of fluorinated reagents suitable for pharmaceutical synthesis, including those necessary for Fluorescite production. Their focus on specialty chemicals and stringent quality controls makes them a key raw material supplier.
Active Pharmaceutical Ingredient (API) Manufacturers
The core component of Fluorescite—the radioactive or radiolabeled molecule—requires high precision manufacturing. Leading API suppliers include:
- Nordion (Canada): As a radiopharmaceuticals specialist, Nordion produces medical isotopes and radiolabeled compounds. Their expertise in isotope production and radiolabeling is fundamental for Fluorescite synthesis.
- Curium Pharma (Germany): Part of IBA Group, Curium is a prominent provider of medical isotopes and radiopharmaceuticals with capabilities aligned for custom API manufacturing for Fluorescite.
- Lantheus Medical Imaging (USA): An established player in diagnostic imaging agents, Lantheus manufactures radiopharmaceutical APIs with high regulatory compliance, serving as a potential supplier for Fluorescite production.
Formulation and Final Drug Product Suppliers
Once APIs are synthesized, formulations are produced by specialized pharmaceutical contractors. Leading firms involved in the final Fluorescite drug product packaging and distribution include:
- Elysium Health: Known for high-quality radiopharmaceutical formulations with strict manufacturing standards, often supplying to hospitals and diagnostic centers globally.
- BioNTech (Germany): With capabilities in sophisticated drug formulation, BioNTech is positioning itself to produce final radiopharmaceuticals including Fluorescite for international markets.
- Hahn-Schickard (Germany): A contract development and manufacturing organization (CDMO) focusing on radiopharmaceuticals, including custom synthesis, labeling, and quality control.
Major Geographic Markets and Supply Dynamics
The global supply landscape for Fluorescite balances regional strengths:
- North America: North American suppliers, particularly Nordion and Lantheus, dominate the radiopharmaceutical API segment. The US FDA’s regulatory standards streamline manufacturing for American markets but pose entry barriers for new suppliers.
- Europe: Europe presents a dense network of high-quality API manufacturers such as Curium and BioNTech, benefiting from the EU’s robust regulatory framework. Germany’s leadership in radiopharmaceutical technology positions it as a critical supply hub.
- Asia-Pacific: Countries such as Japan (TCI) and China are emerging as key suppliers due to evolving economies and expanding R&D capabilities. The region’s lower manufacturing costs contribute to increased competitiveness.
Market Challenges and Opportunities
Challenges:
- Regulatory Complexity: Strict international standards for radiopharmaceuticals necessitate high compliance costs, limiting supplier entry and expansion.
- Supply Chain Disruptions: Component shortages, geopolitical tensions, and transportation bottlenecks have intermittently compromised supply continuity for Fluorescite components.
- Specialized Manufacturing: The radioactive nature of parts of Fluorescite's synthesis mandates specialized facilities and trained personnel, constraining supplier options.
Opportunities:
- Emerging Markets: The rapid adoption of nuclear imaging in Asia could incentivize localized supply sources, reducing latency and logistical costs.
- Vertical Integration: Larger pharmaceutical companies increasing control over API and formulation manufacturing can secure supply chains and reduce costs.
- Innovation in Radiochemistry: Advances in synthesis techniques may broaden raw material sources, diversify supply chains, and improve yields.
Strategic Procurement Considerations
- Supplier Qualification: Engage with suppliers possessing validated cGMP facilities and proven regulatory track records for radiopharmaceuticals.
- Partnership Models: Developing joint ventures or licensing arrangements can secure priority supply and reduce dependency on single-source suppliers.
- Supply Chain Diversification: Mixing suppliers across geographies offers resilience against regional disruptions.
- Regulatory Alignment: Ensuring supplier compliance with local and international standards accelerates approval timelines and reduces risk exposure.
Conclusion
The manufacturing and supply of Fluorescite involve a complex ecosystem of raw material suppliers, API producers, and formulation specialists. North American and European entities currently dominate API manufacturing, with Asia-Pacific emerging as a significant player. Stakeholders must focus on supplier qualification, diversification, and regulatory compliance to ensure steady, cost-effective supply chains. Rapid innovation and geographic diversification will be pivotal in meeting global demand for Fluorescite, especially as diagnostic applications expand.
Key Takeaways
- Identify and vet established suppliers such as Merck KGaA, BASF, Nordion, and Curium for raw materials and APIs.
- Prioritize suppliers with proven regulatory compliance in radiopharmaceutical production to minimize approval delays.
- Diversify supply chains geographically to reduce risk from regional disruptions and optimize costs.
- Engage in strategic partnerships or licensing to secure priority access to critical components.
- Monitor technological innovations in radiochemistry to diversify raw material sources and improve yields.
FAQs
Q1: What are the main raw materials used in Fluorescite synthesis?
A: Fluorinated compounds, radiolabeling precursors, and specialty polymers are primary raw materials sourced from chemical suppliers like Merck, BASF, and TCI.
Q2: Who are the leading API manufacturers for radiopharmaceuticals like Fluorescite?
A: Nordion, Curium Pharma, and Lantheus Medical Imaging are prominent API suppliers, owing to their expertise in isotope production and radiolabeling.
Q3: How does regulation impact the supply chain of Fluorescite?
A: Strict compliance with cGMP standards and radiopharmaceutical regulations limits supplier options, increases costs, and prolongs validation processes.
Q4: Which regions are emerging as key suppliers for radiopharmaceutical components?
A: Asia-Pacific, particularly Japan and China, is advancing in radiochemistry manufacturing, offering competitive alternatives.
Q5: What strategies can stakeholders adopt to secure reliable supply of Fluorescite?
A: Diversify suppliers across regions, establish long-term partnerships, ensure compliance, and stay updated on technological developments.
References
[1] “Global Radiopharmaceuticals Market Analysis,” MarketsandMarkets, 2023.
[2] “Radiochemistry and Supply Chain Considerations,” International Atomic Energy Agency (IAEA), 2022.
[3] “Medical Isotope Production and Supply Chain,” Organisation for Economic Co-operation and Development (OECD), 2021.
[4] “Advances in Radiopharmaceutical Manufacturing,” Journal of Nuclear Medicine, 2020.
[5] “Regulatory Framework for Radiopharmaceuticals,” U.S. Food and Drug Administration, 2022.
More… ↓
